Paul B. Huleatt

629 total citations
17 papers, 508 citations indexed

About

Paul B. Huleatt is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, Paul B. Huleatt has authored 17 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Organic Chemistry, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Paul B. Huleatt's work include Synthesis of Indole Derivatives (4 papers), Chemical Synthesis and Analysis (3 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Paul B. Huleatt is often cited by papers focused on Synthesis of Indole Derivatives (4 papers), Chemical Synthesis and Analysis (3 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Paul B. Huleatt collaborates with scholars based in Singapore, Australia and Italy. Paul B. Huleatt's co-authors include Christina L. L. Chai, Hung A. Duong, Péter Mátyus, Beáta Sperlágh, Petra Dunkel, John A. Elix, Giuseppe Campiani, Sandra Gemma, Ettore Novellino and Flóra Gölöncsér and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and Tetrahedron.

In The Last Decade

Paul B. Huleatt

17 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul B. Huleatt Singapore 14 281 108 104 62 57 17 508
Erika M. Milczek United States 11 536 1.9× 242 2.2× 85 0.8× 17 0.3× 169 3.0× 12 812
T. M. Rangarajan India 14 411 1.5× 118 1.1× 139 1.3× 8 0.1× 63 1.1× 44 632
Jonas Sävmarker Sweden 19 622 2.2× 306 2.8× 26 0.3× 22 0.4× 108 1.9× 35 1.2k
Brian T. O’Neill United States 16 547 1.9× 223 2.1× 96 0.9× 9 0.1× 58 1.0× 28 796
А.В. Павлова Russia 14 252 0.9× 135 1.3× 91 0.9× 14 0.2× 52 0.9× 60 519
Guo Zhu Zheng United States 11 312 1.1× 114 1.1× 85 0.8× 19 0.3× 91 1.6× 14 524
N. Volz Germany 8 217 0.8× 137 1.3× 124 1.2× 26 0.4× 32 0.6× 16 426
Oleg V. Ardashov Russia 13 173 0.6× 109 1.0× 52 0.5× 11 0.2× 47 0.8× 33 393
René Milcent France 16 521 1.9× 107 1.0× 60 0.6× 15 0.2× 16 0.3× 41 664
Rambabu Reddi India 15 584 2.1× 164 1.5× 37 0.4× 21 0.3× 72 1.3× 22 705

Countries citing papers authored by Paul B. Huleatt

Since Specialization
Citations

This map shows the geographic impact of Paul B. Huleatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul B. Huleatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul B. Huleatt more than expected).

Fields of papers citing papers by Paul B. Huleatt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul B. Huleatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul B. Huleatt. The network helps show where Paul B. Huleatt may publish in the future.

Co-authorship network of co-authors of Paul B. Huleatt

This figure shows the co-authorship network connecting the top 25 collaborators of Paul B. Huleatt. A scholar is included among the top collaborators of Paul B. Huleatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul B. Huleatt. Paul B. Huleatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Baranyi, Mária, Pier Francesca Porceddu, Flóra Gölöncsér, et al.. (2016). Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease. Molecular Neurodegeneration. 11(1). 6–6. 64 indexed citations
2.
Huleatt, Paul B., Balázs Balogh, Flóra Gölöncsér, et al.. (2015). Novel Arylalkenylpropargylamines as Neuroprotective, Potent, and Selective Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease. Journal of Medicinal Chemistry. 58(3). 1400–1419. 47 indexed citations
3.
Duong, Hung A., et al.. (2013). Regioselective Copper-Catalyzed Carboxylation of Allylboronates with Carbon Dioxide. Organic Letters. 15(15). 4034–4037. 64 indexed citations
4.
Butini, Stefania, Emanuele Gabellieri, Margherita Brindisi, et al.. (2012). Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies. Bioorganic & Medicinal Chemistry Letters. 23(1). 85–89. 13 indexed citations
5.
Dunkel, Petra, Christina L. L. Chai, Beáta Sperlágh, Paul B. Huleatt, & Péter Mátyus. (2012). Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs. 21(9). 1267–1308. 79 indexed citations
6.
Huleatt, Paul B., et al.. (2011). Concise, efficient and practical assembly of bromo-5,6-dimethoxyindole building blocks. Tetrahedron Letters. 52(12). 1339–1342. 16 indexed citations
7.
Butini, Stefania, Emanuele Gabellieri, Paul B. Huleatt, et al.. (2008). An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds. The Journal of Organic Chemistry. 73(21). 8458–8468. 20 indexed citations
8.
Huleatt, Paul B., et al.. (2008). Expedient routes to valuable bromo-5,6-dimethoxyindole building blocks. Tetrahedron Letters. 49(36). 5309–5311. 14 indexed citations
9.
Duong, Hung A., et al.. (2008). Synthesis of Biindolyls via Palladium-Catalyzed Reactions. The Journal of Organic Chemistry. 73(22). 9177–9180. 40 indexed citations
10.
Selvaratnam, S., Joanne Hui Hui Ho, Paul B. Huleatt, Barbara A. Messerle, & Christina L. L. Chai. (2008). Highly efficient catalytic routes to spiroketal motifs. Tetrahedron Letters. 50(10). 1125–1127. 26 indexed citations
11.
Gemma, Sandra, Emanuele Gabellieri, Paul B. Huleatt, et al.. (2006). Discovery of Huperzine A−Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites. Journal of Medicinal Chemistry. 49(11). 3421–3425. 42 indexed citations
12.
Chai, Christina L. L., John A. Elix, & Paul B. Huleatt. (2005). The Synthetic Versatility of Alkoxycarbonyl‐ and Hydroxymethyl‐piperazine‐2,5‐diones.. ChemInform. 36(49). 1 indexed citations
13.
Chai, Christina L. L., John A. Elix, & Paul B. Huleatt. (2005). The synthetic versatility of alkoxycarbonyl- and hydroxymethyl-piperazine-2,5-diones. Tetrahedron. 61(36). 8722–8739. 19 indexed citations
14.
Fattorusso, Caterina, Sandra Gemma, Stefania Butini, et al.. (2005). Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity. Journal of Medicinal Chemistry. 48(23). 7153–7165. 33 indexed citations
15.
Chai, Christina L. L., John A. Elix, Paul B. Huleatt, & Paul Waring. (2004). Scabrosin esters and derivatives: chemical derivatization studies and biological evaluation. Bioorganic & Medicinal Chemistry. 12(22). 5991–5995. 15 indexed citations
16.
Chai, Christina L. L., John A. Elix, & Paul B. Huleatt. (2003). Multi-purpose functionality for the structural elaboration of the piperazine-2,5-dione motif. Tetrahedron Letters. 44(2). 263–265. 6 indexed citations
17.
Chai, Christina L. L., et al.. (1999). The first electrochemical study of epidithiopiperazine-2,5-diones, a special class of α,α′-disulfide bridged cyclic dipeptides. Journal of the Chemical Society Perkin Transactions 2. 389–392. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika M. Milczek Breakdown of academic impact, for papers by T. M. Rangarajan Breakdown of academic impact, for papers by Jonas Sävmarker Breakdown of academic impact, for papers by Brian T. O’Neill Breakdown of academic impact, for papers by А.В. Павлова Breakdown of academic impact, for papers by Guo Zhu Zheng Breakdown of academic impact, for papers by N. Volz Breakdown of academic impact, for papers by Oleg V. Ardashov Breakdown of academic impact, for papers by René Milcent Breakdown of academic impact, for papers by Rambabu Reddi
Rankless by CCL
2026